Q32 Bio (QTTB) Price & Analysis

Compare

850 Followers

QTTB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.35 - $53.79

Previous CloseN/A

Volume113.57K

Average Volume (3M)176.88K

Market Cap

$20.86M

Enterprise Value-$17.96M

Total Cash (Recent Filing)$54.83M

Total Debt (Recent Filing)$18.70M

Price to Earnings (P/E)―

Beta0.83

Next Earnings

Nov 06, 2025

EPS Estimate

-1.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.78

Shares Outstanding12,197,615

10 Day Avg. Volume86,101

30 Day Avg. Volume176,875

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.86

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit197.37

Enterprise Value/Ebitda0.57

Forecast

1Y Price Target

$10.00

Price Target Upside502.41% Upside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe first patients have been dosed in Part B and the open-label extension of Part A of the Phase 2 SIGNAL-AA trial of bempikibart in alopecia areata.

Patient OutcomesAll patients who completed Part A treatment maintained hair after 36 weeks and beyond, with some achieving additional hair growth post-treatment.

Bears Say

Comparative EfficacyBempi's recent AAD update shows a reduction in SALT, but the data is still inferior to JAKs in alopecia areata trials.

Financial ChallengesQTTB will likely need to raise cash to move bempi forward in alopecia areata, indicating financial challenges ahead.

Q32 Bio News

Eight option delistings on August 18th

Option delistings effective August 18th include Q32 Bio Inc (QTTB), Hyperdynamics Corp (HYPD), Bionano Genomics (BNGO), Allurion Technologies...

19d ago

ABTS

ALUR

Q32 Bio Inc. Advances Alopecia Areata Treatment with Phase 2a Trial of Bempikibart

Q32 Bio Inc (($QTTB)) announced an update on their ongoing clinical study. Q32 Bio Inc. is conducting a...

22d ago

QTTB

Q32 Bio Inc. Reports Continued Losses Amid Development Efforts

Q32 Bio Inc ( ($QTTB) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

QTTB

Q32 Bio Appoints New Interim Chief Medical Officer

Q32 Bio ( ($QTTB) ) just unveiled an announcement. On June 20, 2025, Jason Campagna, M.D., Ph.D., resigned...

2M ago

QTTB

Q32 Bio chief medical officer Jason Campagna to depart

Q32 Bio (QTTB) announced the appointment of Adrien Sipos as interim chief medical officer. Sipos succeeds Jason Campagna...

2M ago

QTTB

Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary

OXB has acquired the remaining 10% stake in its US subsidiary from Q32 Bio (QTTB), bringing its ownership,...

3M ago

QTTB

Q32 Bio Stockholders Approve Key Proposals at Annual Meeting

An announcement from Q32 Bio ( ($QTTB) ) is now available. During the Annual Meeting held on April...

3M ago

QTTB

Q32 Bio Inc. Reports Q1 2025 Financial Results

Q32 Bio Inc ( ($QTTB) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

QTTB

Q32 Bio granted Fast Track designation for bempikibart

Q32 Bio (QTTB) announced that the FDA has granted Fast Track designation to Q32 Bio’s bempikibart for the...

4M ago

QTTB

Q32 Bio Board Member Mark Iwicki Resigns

The latest announcement is out from Q32 Bio ( ($QTTB) ). On April 25, 2025, Mark Iwicki announced...

4M ago

QTTB

Q32 Bio doses first patient in both parts of SIGNAL-AA trial

Q32 Bio (QTTB) announced that the company has dosed the first patients in both the Part A open-label...

5M ago

QTTB

Q32 Bio price target lowered to $15 from $16 at Wells Fargo

Wells Fargo lowered the firm’s price target on Q32 Bio (QTTB) to $15 from $16 and keeps an...

6M ago

QTTB

Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures

Q32 Bio Inc (QTTB) has disclosed a new risk, in the Trade Secrets category. Q32 Bio Inc faces...

6M ago

QTTB

Q32 Bio Reports Promising Trial Results and Financials

Q32 Bio Inc ( ($QTTB) ) has released its Q4 earnings. Here is a breakdown of the information...

6M ago

QTTB

QTTB FAQ

What was Q32 Bio’s price range in the past 12 months?

Q32 Bio lowest stock price was $1.34 and its highest was $53.79 in the past 12 months.

What is Q32 Bio’s market cap?

Q32 Bio’s market cap is $20.86M.

When is Q32 Bio’s upcoming earnings report date?

Q32 Bio’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.

How were Q32 Bio’s earnings last quarter?

Q32 Bio released its earnings results on Aug 06, 2025. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$0.978 by $0.198.

Is Q32 Bio overvalued?

According to Wall Street analysts Q32 Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Q32 Bio pay dividends?

Q32 Bio does not currently pay dividends.

What is Q32 Bio’s EPS estimate?

Q32 Bio’s EPS estimate is -1.19.

How many shares outstanding does Q32 Bio have?

Q32 Bio has 12,197,615 shares outstanding.

What happened to Q32 Bio’s price movement after its last earnings report?

Q32 Bio reported an EPS of -$0.78 in its last earnings report, beating expectations of -$0.978. Following the earnings report the stock price went down -1.515%.

Which hedge fund is a major shareholder of Q32 Bio?

Currently, no hedge funds are holding shares in QTTB

Q32 Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-491.67%

Trailing 12-Months

Asset Growth

-46.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Q32 Bio

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.